BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 31077237)

  • 21. Upregulation of SNHG3 expression associated with poor prognosis and enhances malignant progression of ovarian cancer.
    Hong L; Chen W; Wu D; Wang Y
    Cancer Biomark; 2018; 22(3):367-374. PubMed ID: 29758922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression levels of PTEN, HIF-1α, and VEGF as prognostic factors in ovarian cancer.
    Shen W; Li HL; Liu L; Cheng JX
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2596-2603. PubMed ID: 28678326
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
    Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM
    Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of metastin and a G-protein-coupled receptor (AXOR12) in epithelial ovarian cancer.
    Hata K; Dhar DK; Watanabe Y; Nakai H; Hoshiai H
    Eur J Cancer; 2007 Jun; 43(9):1452-9. PubMed ID: 17442564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
    Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
    J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.
    Köbel M; Gradhand E; Zeng K; Schmitt WD; Kriese K; Lantzsch T; Wolters M; Dittmer J; Strauss HG; Thomssen C; Hauptmann S
    Int J Gynecol Pathol; 2006 Apr; 25(2):121-30. PubMed ID: 16633060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.
    Wong RR; Chan LK; Tsang TP; Lee CW; Cheung TH; Yim SF; Siu NS; Lee SN; Yu MY; Chim SS; Wong YF; Chung TK
    Gynecol Obstet Invest; 2011; 72(3):203-7. PubMed ID: 21860208
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low miR-498 expression levels are associated with poor prognosis in ovarian cancer.
    Cong J; Liu R; Wang X; Wang J; Wang H; Hou J
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(24):4762-5. PubMed ID: 26744867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic values of S100 family mRNA expression in ovarian cancer.
    Ma N; Zhu L; Yang L; Cui Y; Zhan Y
    Cancer Biomark; 2019; 25(1):67-78. PubMed ID: 31033462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pericytes Promote Malignant Ovarian Cancer Progression in Mice and Predict Poor Prognosis in Serous Ovarian Cancer Patients.
    Sinha D; Chong L; George J; Schlüter H; Mönchgesang S; Mills S; Li J; Parish C; Bowtell D; Kaur P;
    Clin Cancer Res; 2016 Apr; 22(7):1813-24. PubMed ID: 26589433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
    Hengstler JG; Lange J; Kett A; Dornhöfer N; Meinert R; Arand M; Knapstein PG; Becker R; Oesch F; Tanner B
    Cancer Res; 1999 Jul; 59(13):3206-14. PubMed ID: 10397267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.
    Karlan BY; Dering J; Walsh C; Orsulic S; Lester J; Anderson LA; Ginther CL; Fejzo M; Slamon D
    Gynecol Oncol; 2014 Feb; 132(2):334-42. PubMed ID: 24368280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial‑mesenchymal transition.
    Lu DH; Yang J; Gao LK; Min J; Tang JM; Hu M; Li Y; Li ST; Chen J; Hong L
    Oncol Rep; 2019 Feb; 41(2):917-927. PubMed ID: 30483796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
    Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
    Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
    Chambers SK; Ivins CM; Carcangiu ML
    Int J Cancer; 1998 Oct; 79(5):449-54. PubMed ID: 9761111
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
    Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
    Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
    Wolf D; Wolf AM; Rumpold H; Fiegl H; Zeimet AG; Muller-Holzner E; Deibl M; Gastl G; Gunsilius E; Marth C
    Clin Cancer Res; 2005 Dec; 11(23):8326-31. PubMed ID: 16322292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.